| Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 18729535 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The evidence for traditionally recommended 7- to 14-day duration of antibacterial therapy for community-acquired pneumonia (CAP) is not well established. OBJECTIVES: We endeavoured to assess the effectiveness and safety of shorter than traditionally recommended antibacterial therapy for CAP. METHODS: We performed a meta-analysis of randomized controlled trials (RCTs) comparing short- (< or = 7 days) versus long- (> or = 2 days difference) course therapy for CAP with the same antibacterial regimens, in the same daily dosages. RESULTS: Five RCTs involving adults (including outpatients and inpatients who did not require intensive care) and two RCTs involving children (aged 2-59 months, residing in developing countries) were included. All RCTs were double-blind and assessed patients with CAP of mild to moderate severity. No differences were found between short- (adults 3-7 days; children 3 days) and long- (adults 7-10 days; children 5 days) course regimens (adults - amoxicillin, cefuroxime, ceftriaxone, telithromycin and gemifloxacin; children - amoxicillin) regarding clinical success at end-of-therapy (six RCTs; 5107 patients [1095 adults, 4012 children]; fixed-effect model [FEM]; odds ratio [OR] = 0.89; 95% CI 0.74, 1.07), clinical success at late follow-up, microbiological success, relapses, mortality (seven RCTs; 5438 patients; FEM; OR = 0.57; 95% CI 0.23, 1.43), adverse events (five RCTs; 3214 patients; FEM; OR = 0. 90; 95% CI 0.72, 1.13) or withdrawals as a result of adverse events. No differences were found in subset analyses of adults or children, and of patients treated with no more than 5-day short-course regimens versus at least 7-day long-course regimens. CONCLUSION: No difference was found in the effectiveness and safety of short- versus long-course antimicrobial treatment of adult and paediatric patients with CAP of mild to moderate severity. |
| | |
Authors:
|
George Dimopoulos; Dimitrios K Matthaiou; Drosos E Karageorgopoulos; Alexandros P Grammatikos; Zoe Athanassa; Matthew E Falagas |
Related Documents
:
|
7896925 - The efficacy of time-limited play therapy with maltreated preschoolers. 16465005 - Steroid resistant nephrotic syndrome is sustained remission attainable. 12631135 - Apolipoprotein e in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. 11188585 - Reflex sympathetic dystrophy in children. a physical therapy approach. 9702885 - Preliminary study of frontal lobe 1h mr spectroscopy in childhood-onset schizophrenia. 3675285 - Clinical evaluation of a commercial photorefractor. |
Publication Detail:
|
Type: Journal Article; Meta-Analysis |
Journal Detail:
|
Title: Drugs Volume: 68 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-08-27 Completed Date: 2009-01-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1841-54 Citation Subset: IM |
Affiliation:
|
Alfa Institute of Biomedical Sciences (AIBS), Athens, GreeceDepartment of Critical Care, Attikon University Hospital, University of Athens, Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Age Factors Anti-Bacterial Agents / administration & dosage, adverse effects, therapeutic use* Child, Preschool Community-Acquired Infections / drug therapy* Drug Administration Schedule Follow-Up Studies Humans Infant Pneumonia / drug therapy* Randomized Controlled Trials as Topic Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Approved and investigational uses of modafinil : an evidence-based review.
Next Document: Budesonide/Formoterol pressurized metered-dose inhaler.